Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer’s disease clinical trials

Table 2 Baseline scores across regions ^a

	North America	Western Europe	Australia/South Africa	Japan	Asia	Eastern Europe/Russia	South America/Mexico	Total sample
MMSE at screen, mean ± SD	21.0 ± 3.2^SA,EE,AS	21.0 ± 3.1^SA,EE,AS	21.0 ± 3.0^SA,EE,AS	20.9 ± 2.9^SA,EE,AS	19.8 ± 3.1^JP,AU,WE,NA	20.1 ± 3.0^JP,AU,WE,NA	20.2 ± 3.0^JP,AU,WE,NA	20.8 ± 3.1
MMSE at baseline, mean ± SD	21.0 ± 3.7^SA,EE,AS	20.9 ± 3.4^SA,EE,AS	20.8 ± 3.4^AS	20.9 ± 3.3^AS	19.8 ± 3.4^JP,AU,WE,NA	20.3 ± 3.1^WE,NA	20.3 ± 3.1^WE,NA	20.7 ± 3.5
ADAS-cog11, mean ± SD	22.0 ± 8.9^SA,EE,AS,WE	23.4 ± 8.9^SA,EE,JP,NA	21.9 ± 9.2^SA,EE,AS	21.4 ± 6.7^SA,EE,AS,WE	24.1 ± 7.9^EE,JP,AU,NA	27.3 ± 10.7^{AS,JP,AU, WE,NA}	25.0 ± 8.8^JP,AU,WE,NA	23.1 ± 9.0
ADCS-ADL, mean ± SD	62.4 ± 11.7^{SA,EE,AS,JP,WE}	59.3 ± 13.3^SA,EE,NA	59.6 ± 13.3^SA,EE	60.2 ± 11.4^SA,EE,NA	56.5 ± 14.5^SA,EE,NA	50.9 ± 15.7^{AS,JP, AU, WE,NA}	53.3 ± 14.4^{AS,JP,AU, WE,NA}	59.2 ± 13.5
CDR-SB, mean ± SD	5.1 ± 2.5^SA,EE,AS	5.3 ± 2.6^SA,EE,AS	5.5 ± 2.6^SA,EE,AS	5.1 ± 2.8^SA,EE	4.7 ± 2.6^{SA,EE,AU,WE,NA}	7.0 ± 3.2^{AS,JP,AU, WE,NA}	6.4 ± 2.9^{AS,JP,AU,WE,NA}	5.4 ± 2.7
NPI, mean ± SD	9.2 ± 10.9^{SA,JP,AU, WE}	10.5 ± 11.3^AS,JP,NA	11.9 ± 12.1^AS,JP,NA	6.6 ± 8.6^{SAEE,AU,WE,NA}	7.7 ± 9.2^SA,EE,AU,WE	10.7 ± 11.6^AS,JP	11.9 ± 12.1^AS,JP,NA	9.6 ± 11.0

^aSA = P < 0.01 vs South America/Mexico; EE = P < 0.01 vs Eastern Europe/Russia; AS = P < 0.01 vs Asia; JP = P < 0.01 vs Japan; AU = P < 0.01 vs Australia/South Africa; WE = P < 0.01 vs Western Europe; NA = P < 0.01 vs North America; ADAS-cog11 = 11-item Alzheimer’s Disease Assessment Scale–Cognitive subscale;; ADCS-ADL = Alzheimer’s Disease Cooperative Study–Activities of Daily Living Inventory; CDR-SB = Clinical Dementia Rating scale Sum of Boxes; MMSE = Mini Mental State Examination.

ISSN: 1758-9193